scholarly journals Bilateral Vocal Process Papillomas: Report of a Case

2002 ◽  
Vol 81 (11) ◽  
pp. 790-791 ◽  
Author(s):  
Douglas M. Sidle ◽  
G. Kenneth Haines ◽  
Ken W. Altman
Keyword(s):  
Squamous Cell Carcinoma ◽  
Proton Pump Inhibitor ◽  
Oral Squamous Cell Carcinoma ◽  
Gastroesophageal Reflux ◽  
Proton Pump ◽  
Medical Management ◽  
Surgical Intervention ◽  
Voice Therapy ◽  
Vocal Process ◽  
Adequate Hydration

We describe a case of bilateral vocal process lesions in a 65-year-old man. His history was strongly suggestive of vocal process granulomas: previous gastroesophageal reflux, intubation, smoking, and oral squamous cell carcinoma. Medical management with a proton-pump inhibitor, reflux precautions, voice therapy, and adequate hydration yielded no results. Subsequent surgical intervention revealed that he had squamous papillomas. We also provide a brief review of vocal process granulomas and squamous papillomas.

Potential reasons for proton pump inhibitor failure in the treatment of gastroesophageal reflux disease

2008 ◽  
Vol 149 (40) ◽  
pp. 1881-1888 ◽  
Author(s):  
Márk Juhász ◽  
Zsolt Tulassay
Keyword(s):  
Gastroesophageal Reflux Disease ◽  
Proton Pump Inhibitor ◽  
Gastroesophageal Reflux ◽  
Proton Pump ◽  
Reflux Disease

A protonpumpagátlók (protonpumpa-inhibitorok, PPI) bevezetése új fejezetet nyitott a gastrooesophagealis refluxbetegség (gastroesophageal reflux disease, GERD) kezelésében. A betegek kisebb, de nem jelentéktelen hányadában azonban a PPI sem hatékony. Ilyen esetekben az első kérdés mindig az, hogy a tünetek valóban GERD-nek tulajdoníthatók-e, vagy egyéb betegség után kell kutatnunk. Ha a GERD a legvalószínűbb lehetőség, akkor a további vizsgálatok és a több támadáspontú kezelés előtt fel kell térképeznünk a beteg együttműködését (compliance). Ha az eredménytelen PPI-kezelés hátterében nem helytelenül kezelt GERD áll, akkor számos egyéb kórkép lehetőségét is fel kell vetnünk. Összefoglaló közleményünkben az elkülönítő diagnosztikai kérdésekről adunk áttekintést.

scholarly journals Diaphragmatic Breathing Reduces Belching and Proton Pump Inhibitor Refractory Gastroesophageal Reflux Symptoms

2018 ◽  
Vol 16 (3) ◽  
pp. 407-416.e2 ◽  
Author(s):  
Andrew Ming-Liang Ong ◽  
Laura Teng-Teng Chua ◽  
Christopher Jen-Lock Khor ◽  
Ravishankar Asokkumar ◽  
Vikneswaran s/o Namasivayam ◽  
...  
Keyword(s):  
Proton Pump Inhibitor ◽  
Gastroesophageal Reflux ◽  
Proton Pump ◽  
Diaphragmatic Breathing ◽  
Reflux Symptoms

scholarly journals Efficacy of Vonoprazan for Gastroesophageal Reflux Symptoms in Patients with Proton Pump Inhibitor-resistant Non-erosive Reflux Disease

2018 ◽  
Vol 57 (17) ◽  
pp. 2443-2450 ◽  
Author(s):  
Ryota Niikura ◽  
Atsuo Yamada ◽  
Yoshihiro Hirata ◽  
Yoku Hayakawa ◽  
Akihiro Takahashi ◽  
...  
Keyword(s):  
Proton Pump Inhibitor ◽  
Gastroesophageal Reflux ◽  
Proton Pump ◽  
Reflux Disease ◽  
Reflux Symptoms

scholarly journals Additional Mosapride to Proton Pump Inhibitor for Gastroesophageal Reflux Disease: A Meta-Analysis

2020 ◽  
Vol 9 (9) ◽  
pp. 2705
Author(s):  
Toshihiro Nishizawa ◽  
Kiyoto Mori ◽  
Shuntaro Yoshida ◽  
Hirotoshi Ebinuma ◽  
Osamu Toyoshima ◽  
...  
Keyword(s):  
Gastroesophageal Reflux Disease ◽  
Proton Pump Inhibitor ◽  
Gastroesophageal Reflux ◽  
Symptom Score ◽  
Proton Pump ◽  
Reflux Disease ◽  
Meta Analysis ◽  
Risk Difference ◽  
Cochrane Library ◽  
Significant Heterogeneity

Background and Aim: In gastroesophageal reflux disease (GERD), the additive effect of mosapride to a proton pump inhibitor (PPI) is still controversial. This meta-analysis integrated randomized controlled trials (RCTs) in which mosapride combined with a PPI was compared with a PPI alone in GERD treatment. Methods: RCTs were systematically searched with the PubMed, Cochrane library, Web of Science, and the Igaku-Chuo-Zasshi database. We combined the data from the RCTs with a random effects model, calculated the standardized mean difference (SMD) and pooled the risk difference (RD) with 95% confidence intervals (CIs). Results: We included nine RCTs in the present meta-analysis. In the mosapride combined with PPI group, the improvement of the symptom score was significantly greater than that in the PPI alone group without significant heterogeneity (SMD: −0.28, 95% CI: −0.45 to −0.12, p = 0.0007). In the mosapride combined with PPI group, the symptom score after treatment was significantly lower than that in the PPI alone group (SMD: −0.24, 95% CI: −0.42 to −0.06, p = 0.007). Conclusions: Mosapride combined with a PPI significantly improved the reflux symptom score compared with that of PPI alone.

Sign in / Sign up

Export Citation Format

Share Document